While many in the biotech industry were surprised when the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 10-to-6 against approval of Vivus Inc.'s obesity drug Qnexa (phentermine/topiramate) on Thursday, the aftermath was somewhat more predictable. (BioWorld Today) Read More
